Omnicell, Inc. (NASDAQ:OMCL) Receives $59.86 Consensus Target Price from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been assigned an average recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $59.8571.

Several brokerages have issued reports on OMCL. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. KeyCorp increased their target price on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Wells Fargo & Company increased their target price on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, April 23rd. Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Finally, Benchmark reiterated a “buy” rating on shares of Omnicell in a research note on Friday, March 13th.

Omnicell Stock Performance

Shares of OMCL stock opened at $43.82 on Wednesday. The stock’s 50-day moving average is $37.71 and its two-hundred day moving average is $40.60. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of 99.59, a PEG ratio of 1.12 and a beta of 0.96. Omnicell has a 1 year low of $26.84 and a 1 year high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. The company had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Analysts predict that Omnicell will post 1.31 earnings per share for the current year.

Insider Activity

In other news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the sale, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This trade represents a 4.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 15,520 shares of company stock valued at $607,610 in the last quarter. Insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. boosted its stake in shares of Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock worth $11,698,000 after buying an additional 117,556 shares during the period. Peregrine Capital Management LLC acquired a new stake in shares of Omnicell during the fourth quarter worth about $4,804,000. Dynamic Technology Lab Private Ltd boosted its stake in shares of Omnicell by 345.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock worth $971,000 after buying an additional 24,738 shares during the period. Dana Investment Advisors Inc. acquired a new stake in Omnicell in the fourth quarter valued at about $3,445,000. Finally, AlphaQuest LLC lifted its position in Omnicell by 388.4% in the third quarter. AlphaQuest LLC now owns 24,231 shares of the company’s stock valued at $738,000 after purchasing an additional 19,270 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.